PRSS8 Antibody

What is PRSS8 and what are its primary biological functions?

PRSS8 is a membrane-anchored serine protease that metabolizes and moderates the effect of specific substrates. Its key functions include:

• Regulation of insulin secretion via the EGF-EGFR signaling pathway in pancreatic β-cells

• Proteolytic shedding of Epidermal Growth Factor Receptor (EGFR)

• Involvement in glucose-dependent physiological regulation in pancreatic tissue

• Potential role as a biomarker in ovarian cancer (OVC)

Research has demonstrated that PRSS8 promotes insulin secretion by activating EGFR and its downstream signaling, particularly contributing to the first phase of insulin secretion .

What is the molecular structure and weight of PRSS8?

PRSS8 has the following characteristics:

PRSS8 exists in multiple forms including a zymogen (inactive precursor) and an active form. In Western blotting analyses, the upper band typically indicates the zymogen form, while the lower band indicates the active form .

In which tissues and cell types is PRSS8 normally expressed?

PRSS8 expression has been detected in various tissues:

• Pancreatic β-cells (co-localized with insulin-positive cells)

• Prostate tissue (normal and cancerous)

• Kidney tissue (particularly in nephrons)

• Ovarian tissue (with higher expression in certain ovarian cancers)

Immunohistochemical analysis has shown that PRSS8 is expressed in the cell membrane and endoplasmic reticulum membrane along with insulin granules in pancreatic β-cells . It also co-stains with N-cadherin, a cell membrane protein .

How is PRSS8 expression regulated in response to physiological stimuli?

PRSS8 expression is dynamically regulated by metabolic conditions:

• Glucose exposure increases PRSS8 expression in pancreatic β-cells

• PRSS8 expression in isolated islets from wild-type mice under refeeding conditions is markedly higher than in mice under fasting conditions

• Long-term high-sucrose diet (HSD) feeding reduces PRSS8 expression in islets, suggesting its pathological contribution to diabetes

• Glucose-dependent upregulation of PRSS8 expression correlates with adequate insulin secretion

Mechanistically, glucose appears to regulate PRSS8 protein levels not through increased transcription but by suppressing protein degradation. After treatment with cycloheximide (a protein synthesis inhibitor), PRSS8 degradation was suppressed under high-glucose conditions .

What are the most common applications for PRSS8 antibodies in research?

PRSS8 antibodies are used in multiple research applications:

For Western blotting, PRSS8 antibodies have successfully detected the protein in human prostate tissue, LNCaP human prostate cancer cell line, PC-3 human prostate cancer cell line, and DU145 human prostate carcinoma cell line . In immunohistochemistry, specific staining is typically localized to the cytoplasm and cell membrane .

How should researchers select the appropriate PRSS8 antibody for their research?

Selection criteria should include:

• Target species reactivity (human, mouse, rat)

• Application compatibility (WB, IHC, ELISA)

• Clonality (monoclonal vs. polyclonal)

• Epitope recognized (specific region of PRSS8)

• Validation data in relevant experimental systems

Different antibodies may recognize distinct forms of PRSS8. For instance, some may detect both zymogen and active forms, while others might be specific to one form. Review validation data showing the specific band pattern in Western blots to ensure the antibody detects the form of interest .

What are the optimal conditions for detecting PRSS8 by Western blot?

Based on published protocols, optimal Western blot conditions include:

• Protein amount: 20 μg of total protein per lane

• Separation: 12.5% SDS-PAGE for optimal resolution

• Membrane: PVDF membrane shows good results

• Antibody dilution: Typically 1:500-1:2000 depending on the specific antibody

• Blocking: 5% BSA in PBS/0.1% Tween-20

• Detection: ECL (Amersham ECL Western Blotting Detection Reagents)

For optimal results, running samples under reducing conditions is recommended for most antibodies, though some protocols specify non-reducing conditions . Immunoblot Buffer Group 1 has been successfully used in published studies .

How should tissue samples be prepared for immunohistochemical detection of PRSS8?

Recommended IHC protocol based on published research:

• Fix tissue in an appropriate fixative (e.g., formalin) and embed in paraffin

• Section tissues (typically 4-6 μm thickness)

• Deparaffinize and rehydrate sections

• Perform antigen retrieval:

  • Using TE buffer pH 9.0 (recommended for many PRSS8 antibodies)

  • Alternatively, citrate buffer pH 6.0 may be used

• Block endogenous peroxidase with 0.3% H₂O₂ for 15 min

• Mark sections with a hydrophobic PAP pen and block with 5% BSA in PBS/0.1% Tween-20 for 30 min at 37°C

• Incubate with primary antibody overnight at 4°C (dilution 1:50-1:500)

• Wash three times in PBS/0.1% Tween-20 for 5 min each

• Incubate with appropriate secondary antibody for 30 min at room temperature

• Develop with DAB and counterstain with hematoxylin

• Dehydrate, clear, and mount for microscopy

What methods are suitable for detecting PRSS8 in serum or other body fluids?

For serum PRSS8 detection:

• Sample preparation:

  • Deplete abundant proteins using methods such as Affinity column ProteoPrep Blue Albumin and IgG Depletion Kit

  • Determine protein concentrations using Bradford Assay

• Detection methods:

  • Western blot: Using 20 μg of total protein resolved by 12.5% SDS-PAGE

  • Microarray technology: Has been used to measure serum prostasin levels in OVC patients and normal individuals

  • ELISA: Can be used for quantitative measurements

Research has shown that serum prostasin mean level was 13.7 μg/ml in ovarian cancer patients compared to 7.5 μg/ml in control subjects, suggesting potential use as a biomarker .

How does PRSS8 contribute to insulin secretion in pancreatic β-cells?

PRSS8 regulates insulin secretion through several mechanisms:

• EGFR signaling pathway:

  • PRSS8 activates EGFR through proteolytic shedding

  • Activated EGFR promotes insulin secretion via downstream signaling

  • Erlotinib (EGFR inhibitor) blocks both EGF- and glucose-stimulated insulin secretion, confirming this pathway

• Glucose-dependent regulation:

  • PRSS8 expression increases in response to glucose

  • This upregulation correlates with enhanced insulin secretion

  • PRSS8 particularly contributes to the first phase of insulin secretion

In experimental models:

• Pancreatic β-cell-specific PRSS8 knockout (βKO) mice develop glucose intolerance and reduced glucose-stimulated insulin secretion

• PRSS8-overexpressing (βTG) mice show enhanced insulin secretion in response to glucose

• PRSS8 depletion in MIN6 cells reduces insulin secretion and impairs EGFR signaling

What is the potential of PRSS8 as a biomarker for ovarian cancer?

Research has established PRSS8 as a promising biomarker for ovarian cancer:

• Sensitivity and specificity of PRSS8 as a biomarker was calculated as high as 92% and 94%, respectively

• PRSS8 mRNA levels were 120 to 410-fold higher in OVC patients than normal controls

• Post-operation levels of PRSS8 declined significantly in most patients, indicating potential use as a prognostic biomarker

• When combined with CA125 (common OVC biomarker), sensitivity increased to 92% and specificity to 94%

• CA125 and PRSS8 show low correlation in expression, suggesting they function in different pathways and may be complementary as biomarkers

These findings suggest PRSS8 could be particularly valuable for early detection of ovarian cancer, addressing a critical clinical need.

What experimental models are available for studying PRSS8 function in vivo?

Several genetic mouse models have been developed:

• Pancreatic β-cell-specific models:

  • PRSS8 knockout (βKO) mice: RIP-Cre+/−PRSS8lox/lox

  • PRSS8-overexpressing (βTG) mice: Generated using rat insulin II promoter expression vector

• Kidney-specific models:

  • Inducible nephron-specific PRSS8 knockout mice

  • Double knockout models with other proteases (e.g., CAP3/St14)

These models allow for tissue-specific investigation of PRSS8 function in physiological and pathological contexts.

How can researchers address contradictory findings regarding PRSS8 function?

When faced with contradictory findings:

• Consider tissue-specific effects:

  • PRSS8 may have different functions in different tissues

  • Expression patterns vary between tissue types

• Evaluate experimental conditions:

  • Short-term vs. long-term effects (e.g., short-term glucose loading increased PRSS8, while long-term high-sucrose diet decreased it)

  • In vitro vs. in vivo models may show different results

• Assess methodological differences:

  • Antibody specificity and epitope recognition can affect results

  • Experimental readouts may differ (mRNA vs. protein levels)

• Consider interaction with other pathways:

  • PRSS8 interacts with multiple signaling pathways (EGFR, PI3K, AKT, ERK)

  • Context-dependent effects may depend on the status of these pathways

The study by Komatsu et al. (2023) noted three key limitations in PRSS8 research: not addressing all PRSS8 mechanisms in β-cells, difficulty in examining effects on insulin secretion and β-cell proliferation independently, and incomplete investigation of pathological modifications in mouse pancreatic islets .

Why might PRSS8 antibodies show different molecular weights in Western blot?

Variations in observed molecular weight may occur due to:

• Different forms of PRSS8:

  • Zymogen (inactive precursor) vs. active form

  • The active form is generated after proteolytic processing

• Post-translational modifications:

  • Glycosylation, phosphorylation, or other modifications

  • Cell-type specific processing

• Experimental conditions:

  • Reducing vs. non-reducing conditions

  • Percentage of acrylamide in gels (reported optimal: 12.5%)

Published observations show:

• Upper band (~40-50 kDa): typically zymogen form of PRSS8

• Lower band (~36-39 kDa): typically active form

• Simple Western lane view shows a specific band at approximately 50 kDa in human prostate tissue and LNCaP cell lysates

What validation steps are necessary when using new PRSS8 antibodies?

Recommended validation steps include:

• Positive and negative controls:

  • Use tissues known to express PRSS8 (prostate, pancreas, kidney)

  • Include knockout tissue/cells where available (e.g., βKO mice islets)

  • Protein lysates from inducible nephron-specific PRSS8 knockout mice can serve as negative controls

• Specificity tests:

  • Peptide competition assays to confirm specificity

  • Multiple antibodies targeting different epitopes should show similar patterns

  • Correlation with mRNA expression data

• Cross-validation with different techniques:

  • Compare IHC, WB, and qRT-PCR results

  • Confirm cellular localization through immunofluorescence

  • Consider immunoelectron microscopy for subcellular localization

• Application-specific optimization:

  • Determine optimal dilutions for each application

  • Test different antigen retrieval methods for IHC (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Optimize blocking conditions to reduce background

What are promising areas for future PRSS8 research?

Based on current literature, promising research directions include:

• Therapeutic targeting in diabetes:

  • Exploring PRSS8 modulators to enhance insulin secretion

  • Investigating the relationship between PRSS8 dysfunction and diabetes development

  • Understanding long-term effects of PRSS8 overexpression on β-cell function

• Cancer diagnostics and therapeutics:

  • Further development of PRSS8 as an early detection biomarker for ovarian cancer

  • Exploring potential in other cancer types

  • Investigating PRSS8's role in cancer progression and metastasis

• Signaling pathway interactions:

  • Deeper exploration of PRSS8's role in EGFR signaling

  • Investigation of interactions with other pathways (PI3K, AKT, ERK)

  • Identification of additional PRSS8 substrates beyond EGFR

• Tissue-specific functions:

  • Comparative studies across different tissues expressing PRSS8

  • Exploration of compensatory mechanisms in PRSS8-deficient models

  • Investigation of PRSS8's role in tissue development and homeostasis

Understanding these aspects could lead to novel therapeutic approaches for diabetes, cancer, and other conditions where PRSS8 plays a significant role.